Hyperlipidemias: Ferrières J

Bongard V, Ferrières J. · Service d'épidémiologie, CHU de Toulouse, faculté de médecine. · Rev Prat. · Pubmed #16548253 No free full text.

This publication has no abstract.

Dallongeville J, Ferrières J, Schuster H, Farnier M, Lepen C. · INSERM U508, Institut Pasteur, Lille, France. · Presse Med. · Pubmed #15523276 No free full text.

This publication has no abstract.

Ferrières J. · Service de Cardiologie, CHU Purpan, 31059 Toulouse. · Ann Cardiol Angeiol (Paris). · Pubmed #12555337 No free full text.

Abstract: In the context of the growing complexity of atherosclerosis, LDL-cholesterol has been gradually revealed to be the main aetiological agent. However, the first clinical trials were not convincing, as they failed to demonstrate a significant improvement of coronary mortality. So-called "regression" trials revealed the need to develop clinical trials in which the primary endpoint is coronary events and no longer intermediate criteria such as the course of coronary disease on coronary angiography. Lovastatin, simvastatin and pravastatin were shown to be effective in the prevention of relapses in coronary patients and in the prevention of coronary events in healthy subjects. In 1999, the prescription for coronary patients should almost always include a statin and the prescription in healthy subjects should include a statin when this subject presents a high risk of coronary events in the years to come.

Marques-Vidal P, Arveiler D, Amouyel P, Ducimetière P, Ferrières J. · INSERM U558, Faculté de Médecine Purpan, Département d'Epidémiologie, 1er ét. 37, Allées Jules Guesde, 31073 Toulouse cedex, France. · Rev Epidemiol Sante Publique. · Pubmed #11845103 No free full text.

Abstract: BACKGROUND: Little is known regarding the cost of cardiovascular risk factor prevention in France. In this study, we assessed the cost of antihypertensive and hypolipidaemic drug treatment in middle-aged French men without history of coronary heart disease. METHODS: A cross-sectional study was conducted between 1991 and 1993 in 1606 subjects treated for hypertension or dyslipidaemia from the three French centres participating in the PRIME study. The daily cost of treatment (in Euros) was assessed using data from the Agence Nationale du Médicament. RESULTS: Mean daily cost of hypertension was 0.65 euro per patient; after multivariate adjustment, obese subjects had a mean daily cost of 0.74+/-0.03 euro (adjusted mean +/- standard error) versus 0.66+/-0.03 euro for non-obese (p<0.001). Only 58% of hypertensive subjects were adequately controlled, and this percentage was higher in the Toulouse centre (80.1%) than in Lille (44.4%) or Strasbourg (50.2%), p<0.001. Fibrates were the most frequently prescribed hypolipidemic drug; nevertheless, prescription of statins was higher than fibrates in the Toulouse centre, which led to a higher mean daily cost for dyslipidaemia, which was further confirmed by multivariate adjustment: 0.59+/-0.05 euro (adjusted mean +/- standard error) in Toulouse versus 0.44+/-0.04 euro in Lille and 0.44+/-0.04 euro in Strasbourg. Only 54% of treated dyslipidemic subjects had their lipid levels within normal values, and this percentage was significantly lower (44%) in Strasbourg than in Lille (58%) or Toulouse (59%) (p<0.001). CONCLUSION: The prescription of anti-hypertensive or hypolipidemic drugs differs according to centre, leading to significant differences in mean daily cost of treatment. A considerable percentage of treated subjects is not adequately controlled, with possible consequences at the economical level.

Royer M, Bulai Livideanu C, Periquet B, Maybon P, Lamant L, Mazereeuw-Hautier J, Ferrières J, Paul C. · Service de dermatologie, université Paul-Sabatier, CHU Toulouse-Purpan, 1, place du Dr-Baylac, Toulouse, France. · Ann Dermatol Venereol. · Pubmed #19171229 No free full text.

Abstract: BACKGROUND: Type III hyperlipoproteinaemia (HLP) is a rare form of dyslipidaemia characterized by skin lesions such as palmar crease xanthoma and tuberous xanthomas. To our knowledge, there have been no previous reports of yellow-orange discoloration of the skin and xanthomas associated with this disease. CASE REPORT: A 61-year-old woman consulted for palmar crease xanthoma and tuberous xanthomas of the elbows with odd yellow-orange discoloration. Laboratory investigations demonstrated type-III HLP and a high serum lycopene level. After 14 weeks of lipid-lowering treatment, the xanthomas and discoloration showed improvement. In addition, lipid levels and serum lycopene had returned to normal. DISCUSSION: All cases of lycopenaemia reported in the literature followed excessive ingestion of lycopene in foods. We describe the first case of lycopenaemia with orange discoloration of xanthomas following raised serum lycopene but not involving excessive dietary intake. Type-III HLP was doubtless instrumental in the physiopathogenesis of these orange lesions.

Goumidi L, Spengler D, Cottel D, Wagner A, Ducimetière P, Ruidavets JB, Legry V, Arveiler D, Bingham A, Ferrières J, Amouyel P, Meirhaeghe A. · INSERM, U744, Lille, France. · J Hypertens. · Pubmed #19155788 No free full text.

Abstract: OBJECTIVES: ZAC1 (zinc finger protein regulating apoptosis and cell cycle arrest) is a member of the new subfamily of zinc-finger transcription factors, designated as PLAG (pleomorphic adenoma gene) family. The ZAC1 gene is maternally imprinted and is linked to developmental disorders such as growth retardation and transient neonatal diabetes mellitus. We wanted to assess whether the genetic variability of the ZAC1 gene was associated with anthropometric (weight, BMI, waist-to-hip ratio) or biochemical (plasma lipid, insulin, glucose levels, blood pressure level) phenotypes. METHODS: We selected 37 independent SNPs (single nucleotide polymorphisms) or tagSNPs in the ZAC1 locus from the literature and several databases and, based on the linkage disequilibrium map, identified 27 independent SNPs. Those 27 SNPs were genotyped in a French population-based sample (n = 1155). Associations with a P value lower than 0.0019 (Bonferroni correction) were considered significant. RESULTS: We found that women carrying the T allele of rs9403542 had lower waist-to-hip ratio (P = 0.0006) than women with the CC genotype. Also, men bearing the T allele of rs13218225 had lower systolic (P = 3.6 x 10(-5)) and diastolic (P = 4.1 x 10(-4)) blood pressure than GG men. As a consequence, the adjusted (for age, smoking habit, alcohol consumption, physical activity level and BMI) odds ratio (95% confidence interval) of hypertension for T allele carrier men was 0.55 [0.35-0.86], P = 0.009. We genotyped two other independent samples (MONICA Toulouse, n = 1130 and MONICA Strasbourg, n = 1048) for rs9403542 and rs13218225 but we could not confirm these associations. CONCLUSION: We found no evidence that polymorphisms in ZAC1 might influence anthropometric, biochemical or clinical parameters in French individuals.

Ferrières J, Gousse ET, Fabry C, Hermans MP, Anonymous00022. · Service de cardiologie B, CHU Rangueil, TSA 50032, 31059 Toulouse cedex 9, France. · Arch Cardiovasc Dis. · Pubmed #19041840 No free full text.

Abstract: OBJECTIVE: Most evidence-based practice guidelines identify low-density lipoprotein cholesterol (LDL-C) as the primary target of cholesterol-lowering therapy; the optimal LDL-C concentration is based on the patient's individual risk level. The aim of this study was to determine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended in guidelines. METHODS: The CEPHEUS study was conducted in eight European countries in patients, who had been treated with lipid-lowering drugs for at least three months, with no dose adjustment for a minimum of six weeks. In France, throughout 2006, 560 general practitioners enrolled 2222 patients into the study, 1966 of whom gave a fasting blood sample. Lipid and glucose parameters were measured centrally. RESULTS: Patients had been on treatment for a mean of 5.5+/-5.7 years. Most patients (90.4%) received a single lipid-lowering drug; 84.9% were treated with statins, and the second most frequently used lipid-lowering drugs were fibrates (13.7%). Among the treated subjects, 50% had LDL-C values>3.0 mmol/L, 30% had triglyceride values>1.7 mmol/L and 10% had HDL cholesterol values<1.1 mmol/L. In high-risk patients, as defined by French guidelines, over 55% were above the recommended goal of 2.6 mmol/L. In the subgroup of high-risk patients who did not reach the goals, the LDL-C values were 0.7-1.4 mmol/L over the recommended concentration. CONCLUSION: The results of this survey highlight the suboptimal management of hypercholesterolaemia in France, particularly in the high-risk population, in whom the percentage who achieved the LDL-C goals was the lowest.

Bruckert E, Giral P, Paillard F, Ferrières J, Schlienger JL, Renucci JF, Abdennbi K, Durack I, Chadarevian R, Anonymous00067. · Groupe hospitalier Pitié-Salpétrière, Service d'Endocrinologie-Métabolisme, 47-83, Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. · Cardiovasc Drugs Ther. · Pubmed #18830810 No free full text.

Abstract: BACKGROUND: Many studies have demonstrated a gap between guidelines for the prevention of cardiovascular disease (CVD) and their implementation in clinical practice. AIM: The PEGASE education program has been devised with an aim to improve the management of patients at high risk of CVD. METHODS: In a multicentre study carried out from 2001-2004 in France, 96 participating physicians were randomized into a "trained" group, which included 398 "educated" patients, and a "non-trained" group, which included 242 "non-educated" patients. Educated patients received six hospital-based educational sessions, four collective and two individual. Framingham score, smoking, lipid levels, glycaemia, blood pressure, dietary intake and drug compliance, as well as quality of life, were evaluated at baseline (M0) and 6 months (M6). The primary endpoint of the study was the efficacy of the PEGASE program in reducing global CVD risk in high-risk patients. RESULTS: The Framingham score was calculated for 473 patients. The Framingham score improved significantly at M6 vs M0 in the educated group (13.0 +/- 8.21 vs 13.6 +/- 8.48, d = -0.658, p = 0.016), but not in the non-educated group (12.5 +/- 8.19 vs 12.4 +/- 7.81, d = +0.064, p = 0.836); the mean change between the two groups did not reach significance. Quality of life, LDL-c level and diet scores improved in the "educated" group only. CONCLUSIONS: The PEGASE education program improved risk factors for CVD, although global assessment by Framingham score was not significantly different between groups. This program, aimed at meeting needs and expectations of patients and physicians, was easily implemented in all hospital centres.

Hansel B, Nicolle C, Lalanne F, Tondu F, Lassel T, Donazzolo Y, Ferrières J, Krempf M, Schlienger JL, Verges B, Chapman MJ, Bruckert E. · Service d'Endocrinologie-Métabolisme, AP-HP, Hôpital de la Pitié, Paris, France. · Am J Clin Nutr. · Pubmed #17823447 links to  free full text

Abstract: BACKGROUND: Plant sterol (PS)-enriched foods have been shown to reduce plasma LDL-cholesterol concentrations. In most studies, however, PSs were incorporated into food products of high fat content. OBJECTIVE: We examined the effect of daily consumption of PS-supplemented low-fat fermented milk (FM) on the plasma lipid profile and on systemic oxidative stress in hypercholesterolemic subjects. DESIGN: Hypercholesterolemic subjects (LDL-cholesterol concentrations >or=130 and <or= 190 mg/dL; n = 194) consumed 2 low-fat portions of FM in the same meal daily for 6 wk. Subjects were randomly assigned to 2 groups: low-fat FM enriched with 0.8 g PS ester per portion or control FM. Plasma concentrations of lipids, oxidized LDL, beta-carotene, beta-sitosterol, campesterol, and high-sensitivity C-reactive protein were measured during the trial. RESULTS: Plasma LDL-cholesterol concentrations were reduced by 9.5% and 7.8% after 3 and 6 wk, respectively, in the 1.6-g/d PS group compared with the control group, whereas plasma triacylglycerol and HDL-cholesterol concentrations were not significantly affected. In addition, there were no significant changes in serum beta-carotene on normalization to LDL cholesterol during the study period in both groups, whereas plasma concentrations of oxidized LDL were reduced significantly in the PS group compared with the control group (-1.73 compared with 1.40 U/L, respectively; P < 0.05). Plasma sitosterol concentrations were increased by 35% (P < 0.001 compared with control); however, campesterol concentrations did not change during the study period. CONCLUSION: Daily consumption of 1.6 g PS in low-fat FM efficiently lowers LDL cholesterol in subjects with moderate hypercholesterolemia without deleterious effects on biomarkers of oxidative stress.

Grondin MA, Ouchchane L, Ferrières J, Gerbaud L. · Unité épidémiologie, économie de la santé et prévention, Délégation qualité, Département de santé publique, Hôtel-Dieu, Clermont-Ferrand (63). · Presse Med. · Pubmed #17028530 No free full text.

Abstract: INTRODUCTION: The SPOT epidemiologic survey assessed the results of long-term cholesterol-lowering therapy in France and the reasons why patients do or do not meet their therapeutic objectives. OBJECTIVE: To assess the guidelines on which doctors base their practices for cholesterol-lowering therapy and make suggestions to improve the match between recommendations and practices. METHODS: LDL cholesterol was measured in 2479 French outpatients in 2003 and classified according to whether it met therapeutic objectives of 3 different scales: the official French (AFSSAPS) recommendations issued in 2000, the physician's opinion of the ideal level for the patient, and the physician's goal level for the patient. Agreement between these 3 criteria was analyzed. RESULTS: French doctors used guidelines stricter than the official recommendations to assess the achievement of lipid-lowering objectives. DISCUSSION: Physicians rely more on American than French guidelines. They also considered the patient's history and clinical condition in setting individual goals.

Ferrières J, Ruidavets JB, Perret B, Dallongeville J, Arveiler D, Bingham A, Amouyel P, Haas B, Ducimetière P. · INSERM U558, Département d'Epidemiologie, Faculté de Médecine, Toulouse. · Arch Mal Coeur Vaiss. · Pubmed #15787304 No free full text.

Abstract: Prevalence of dyslipidaemias in a representative sample of the French population Hypercholesterolaemia is a major factor of risk of coronary atherosclerosis. The prevalence of other types of dyslipidaemia in the general population remains poorly defined. This study was performed to measure the prevalence of various dyslipidaemias in the French population. A representative sample of 3508 men and women between the ages of 35 and 64 years was recruited by the "Multinational MONItoring of trends and determinants in CArdiovascular disease" centres of Lille, Strasbourg and Toulouse. We excluded 162 patients suffering from known cardiovascular disorders, and 409 individuals treated with lipid-lowering drugs. The prevalence of pure hypercholesterolaemia, defined as a total cholesterol concentration >6.2 mmol/l (2.4 g/l) and triglyceride concentration <2.3 mmol/l (2 g/l), was 30% (29-32%). The prevalence of HDL cholesterol concentration <1 mmol/l (0.4 g/l) in men, or <1.3 mmol/l (0.5 g/l) in women, was 12% (11-13%). The prevalence of mixed hyperlipidaemia, defined as a total cholesterol concentration >6.2 mmol/l (2.4 g/l) and triglyceride concentration >2.3 mmol/l (2 g/l) was 5% (4-6%). The prevalence of hypertriglyceridaemia, defined as a total cholesterol concentration <6.2 mmol/l (2.4 g/l) and triglyceride concentration >2.3 mmol/l (2 g/l) was 4% (3-5%). Low HDL cholesterol concentrations were associated with smoking, obesity, and absence of either regular physical exercise or alcohol consumption. This study confirmed the high prevalence of pure hypercholesterolaemia, and revealed an important prevalence of low HDL cholesterol concentration, which represents a major cardiovascular risk factor.

Ferrières J, Lablanche JM, Pouchain D, Girerd X, Krempf M, Nguyen G, Glanddier PY. · Unité de prévention de l'athérosclérose, service de cardiologie B, CHU Rangueil, Toulouse. · Arch Mal Coeur Vaiss. · Pubmed #15724421 No free full text.

Abstract: The objective of the SPOT study (Study of Practice versus Objectives of Treatment) was the biochemical evaluation of the results of long term lipid regulating treatment in France, compared to the objectives defined by AFSSAPS (French regulatory agency for the safety of medical products) in 2000. A random sample of doctors was recruited in 21 French regions by the Regional Health Observation service. To be included in the SPOT study, the patients had to be on lipid regulating medication for at least six months and consent to biochemical evaluation following a consultation. A sample of 641 doctors examined 2,479 patients treated for 7 years on average. These middle aged patients (aged 63 +/- 11 years) were mostly taking statins (72%). They had an average total cholesterol level of 5.41 +/- 1.01 mmol/L (2.10 +/- 0.39 g/L). and LDL of 3.25 +/- 0.93 mmol/L (1.26 +/- 0.36 g/L), reflecting previous results and confirming the stability of their treatment. In primary prevention and in low risk subjects (with less than 2 associated risk factors), the AFSSAPS objectives were achieved in 95% of cases. In secondary prevention or in very high risk subjects (at least 3 associated risk factors 0), 35% of patients had LDL cholesterol greater than 3.4 mmol/L (1.30 g/L). The SPOT study, performed on subjects who had in theory been stabilised with lipid regulating medication, gave two conclusions: cardiovascular prevention with lipid regulating medication is improving in France, and the subjects at greatest risk attain the recommended objectives less often despite the expected benefit of treatment being higher.

Cournot M, Cambou JP, Ferrières J, Grenier O, Herrmann MA, Cantet C, Leizorovicz A. · INSERM U5558, Département d'épidémiologie, Faculté de médecine, Toulouse. · Arch Mal Coeur Vaiss. · Pubmed #15521475 No free full text.

Abstract: INTRODUCTION: Myocardial infarction (MI), peripheral vascular disease and ischaemic cerebral vascular accident (CVA) are three manifestations of the same disease, atherothrombosis, and they share the same pathophysiology and prognosis. OBJECTIVE: The aim of this work was to describe the clinical characteristics and the medical management of polyvascular patients in cardiology. METHOD: Cardiologists from all over the country participated in a consultation register for 3 weeks. The clinical characteristics and medical management for the first 3 patients on the register for each cardiologist were studied in a national multicentre study and then compared according to whether the atherothrombotic disease was isolated or polyvascular. RESULTS: In total, 100,429 patients were examined during the period of the register and 2,780 were included in the study. Polyvascular patients represented 7% of the register and 22% of the vascular patients. These patients with multiple manifestations were frequently diabetics. A lipid profile was available less often in the cardiac patients when they had another disorder (72.4%) than in the case of an isolated disorder (78.9%). Whatever the initial disorder, dyslipidaemia was less often controlled in the case of polyvascular disease (63% of LDL-C > or = 1.3g/l in polyvascular cardiac patients vs 52% in cardiac patients with isolated disease). In cardiac patients, the presence of peripheral vascular disease was associated with less prescription of beta blockers (OR=0.4 [0.3-0.6]), the presence of CVA was associated with less prescription of statins (OR=0.7 [0.5-0.9]). Eight out of 10 polyvascular patients received anti-platelet aggregation treatment. The presence of multiple atherothrombotic manifestations was associated with greater prescription of ACEI, except in cardiac patients. CONCLUSION: These results improve our understanding of the specific management of polyvascular patients, for whom secondary prevention is paramount due to the higher risk of recurrence. They should prompt the reinforcement of measures which have been shown to be effective, such as managing major risk factors, and in particular the dislipidaemias.

Bongard V, Ruidavets JB, Dallongeville J, Simon C, Amouyel P, Arveiler D, Ducimetière P, Ferrières J. · Department of Epidemiology, INSERM U558, Faculté de Médecine, Toulouse, France. · Eur J Clin Nutr. · Pubmed #15116082 No free full text.

Abstract: OBJECTIVE: To compare the dietary intakes of free-living people with and without previously diagnosed diet-modifiable cardiovascular risk factors (hypertension, hypercholesterolaemia and diabetes). DESIGN: Cross-sectional survey on cardiovascular risk factors including a three-consecutive-day food record. SETTING: Multicentre setting in Lille (northern France), Strasbourg (north-east) and Toulouse (south-west) areas. SUBJECTS: A total of 1072 middle-aged men randomly selected from the general population: group 1 (504 men without previously diagnosed diet-modifiable risk factor), group 2 (377 men with one previously diagnosed diet-modifiable risk factor) and group 3 (191 men with two or three previously diagnosed diet-modifiable risk factors). INTERVENTIONS: None. RESULTS: Total daily energy intake equalled 10731 kJ/day (standard error: 119), 9991 (138) and 9737 (166) in groups 1, 2 and 3, respectively (P<0.0001 for ANOVA comparing the three groups), and daily energy intake without alcohol equalled 9860 (115), 9096 (132) and 8654 (159) kJ/day (P<0.0001). The proportion of calories from animal proteins (in daily energy intake without alcohol) increased from group 1 to 3 (P<0.0001), whereas the proportion from oligosaccharides decreased (P<0.0001). The proportion of calories from alcohol (in total daily energy intake) increased with the number of risk factors (P<0.0001). These results remained significant after adjustment for confounders. No significant group differences were found in the proportions of energy from polysaccharides, saturated, monounsaturated and polyunsaturated fats. CONCLUSIONS: As compared with subjects without risk factor, significant quantitative and qualitative changes are observed in individuals with diagnosed hypertension, hypercholesterolaemia or diabetes. However, lower consumptions of saturated fats and alcohol are needed.

Ferrières J, Elbaz M, Maupas E, Carriè D, Puel J. · Service de cardiologie B, Unité de prévention de l'athérosclérose, CHU Rangueil, Toulouse 9. · Arch Mal Coeur Vaiss. · Pubmed #15106741 No free full text.

Abstract: The objective of this study was to compare the results of the management of dyslipidaemic patients in the community with the objectives fixed by the AFSSAPS recommendations. An observational epidemiological study was set up among 4 000 general practitioners and 527 cardiologists. This study included 22 323 patients (average age 60.6 years) affected by a documented primary dyslipidaemia. The average number of associated risk factors, according to the AFSSAPS criteria, was 1.8. The prevalence of secondary prevention in patients was 17.5%. More than 80% of patients were being treated by a lipid lowering agent (fibrate or statin) combined or not with lifestyle guidelines. In primary prevention, although the target levels of LDL-C fixed by the AFSSAPS were attained in 94.4% and 82.6% respectively for patients with no other risk factor or with one associated risk factor, the objectives were reached in only 55.4% of patients with two other risk factors and in 29.6% of patients with more than two other risk factors. In secondary prevention, the AFSSAPS objectives were attained in only 45.2% of patients. Following this lipid result, 34.8% of patients underwent therapeutic adjustment, principally the use of medication in the patients receiving lifestyle advice or reinforcement of pharmacological treatment. This study underlines the inadequate management in France of dyslipidaemic patients in the community.

Blacher J, Evans A, Arveiler D, Amouyel P, Ferrières J, Bingham A, Yarnell J, Haas B, Montaye M, Ruidavets JB, Ducimetière P, Anonymous00085. · INSERM U 258, Hôpital Paul Brousse, Villejuif, France. · J Hypertens. · Pubmed #15076202 No free full text.

Abstract: OBJECTIVE: Since the proportion of subjects taking antihypertensive and lipid-lowering drugs is currently increasing in industrialized countries, it is important to evaluate, at the population level, coronary risk of treated individuals, while taking into account the achieved level of their risk factors (i.e. their 'residual coronary risk'). DESIGN AND METHODS: We used the data from the Prospective Study of Myocardial Infarction (PRIME), which involved populations from France (three centres) and Northern Ireland (one centre) (in each centre, 2500 men, aged 50-59 years, free of coronary heart disease, with a 5-year follow-up), to analyse the relationships between cardiovascular drug use and subsequent coronary risk. RESULTS: Antihypertensive drug use was significantly positively associated (relative risk = 1.60; 95% confidence interval, 1.18-2.16) with total coronary risk, but not lipid-lowering drug use (relative risk = 1.15; 95% confidence interval, 0.77-1.73), while adjusting on classical risk factor levels (age, smoking, total cholesterol, high-density lipoprotein-cholesterol and systolic blood pressure). Subgroup analysis showed that these results applied to beta-blockers and calcium channel antagonists, but not to diuretics and angiotensin-converting enzyme inhibitors, to both angina pectoris and hard coronary event risk, but in the French population only and not in Belfast. Although the PRIME study was not designed to test the ability of different drugs to prevent coronary heart disease, this analysis raises the hypothesis that antihypertensive drugs could be associated with a sizeable residual coronary risk in middle-aged men. CONCLUSION: Treatment with antihypertensive agents, beta-blockers and calcium channel antagonists in particular, was associated with a sizeable residual coronary risk. It seems, therefore, important to consider antihypertensive treatment in the cardiovascular risk assessment of individuals.

Marques-Vidal P, Ruidavets JB, Amouyel P, Ducimetière P, Arveiler D, Montaye M, Haas B, Bingham A, Ferrières J. · INSERM U558, Faculty of Medicine Purpan, Toulouse, France. · Eur J Epidemiol. · Pubmed #15012019 No free full text.

Abstract: The change in the main cardiovascular risk factors in France was assessed using the MONICA population surveys conducted in the Urban Community of Lille, Bas-Rhin and Haute-Garonne. Trends in obesity, tobacco smoking, hypertension, hypercholesterolaemia and self-reported diabetes were established for the first (1985-1988) and the last (1995-1997) survey. The results indicate that the prevalence of overweight and obesity remained stable in both genders; tobacco smoking decreased in men but increased in women. Prevalence of hypertension decreased, and preventive measures improved in both genders. Prevalence of hypercholesterolaemia remained stable, and preventive measures improved only in men. Prevalence of self-reported diabetes increased solely in women, and preventive measures improved in both genders. However, in 1995-1997 still 40% of the treated hypertensive and 30% of the treated hypercholesterolaemic subjects were not adequately controlled. We conclude that prevalence and prevention of the main cardiovascular risk factors have evolved favourably in France, but the management of hypercholesterolaemia and hypertension can still be improved.

Cottin Y, Cambou JP, Casillas JM, Ferrières J, Cantet C, Danchin N. · Department of Cardiology, Centre Hopsitalier Universitaire de Dijon, France. · J Cardiopulm Rehabil. · Pubmed #14758102 No free full text.

Abstract: PURPOSE: Cardiac rehabilitation after acute coronary syndrome is an important but underused therapeutic intervention. The aim of the French nationwide PREVENIR survey was to improve knowledge on the management of cardiovascular risk factors, especially during cardiac rehabilitation after acute coronary syndrome. The purpose of this study was to specify the characteristics of patients referred to cardiac rehabilitation. METHODS: The survey was performed in 77 of 501 (15.4%) public or private French coronary care units. All French regions were involved. All the patients admitted to the hospital during January 1998 who survived an acute coronary syndrome were included in the survey. Data on rehabilitation practice were collected from patient medical records, either during an outpatient consultation or from the patient and the general practitioner during the 6-month follow-up period. RESULTS: Of the 1394 patients included in the study (779 with myocardial infarction and 615 with unstable angina), only 310 (22%) underwent cardiac rehabilitation. Significant differences in patient characteristics were found between the cardiac rehabilitation and non-cardiac rehabilitation groups, respectively, in terms of gender (82% male vs 68%; P <.001), age younger than 65 years (56% vs 39%; P <.001), type of acute coronary syndrome (75% myocardial infarction vs 50%; P <.001), left ventricular ejection fraction less than 35% (6% vs 13%; P <.0004), and prevalence of percutaneous intervention (54% vs 46%; P <.02). Two risk factors were more common in the rehabilitated group: dyslipidemia (52% vs 44%; P <.02) and current smoking (51% vs 37%; P <.0001). In the multivariate analysis, female gender (odds ratio [OR], 0.6; 95% confidence interval [CI], 0.44-0.87) and older age (>75 years vs. <65 years; OR, 0.40; 95% CI, 0.3-0.7) predicted decreased cardiac rehabilitation prescription. Conversely, previous history of dyslipidemia (OR,1.4; 95% CI, 1.04-1.8), post-myocardial infarction (OR, 2.8; 95% CI, 2.13-3.89), and a percutaneous intervention (OR,1.9; 95% CI, 1.3-2.7) predicted increased cardiac rehabilitation prescription. Severe left ventricular impairment (< or =35% vs >50%) was not an independent factor for cardiac rehabilitation prescription. At 6-month follow-up assessment, rehabilitation patients had a lower rate of hypertension (18% vs 27%), elevated low-density lipoprotein cholesterol (54% vs 62%), and continued smoking (34% vs 50%). CONCLUSIONS: The results of the PREVENIR survey underscore the low level of cardiac rehabilitation prescription in France, and the relative exclusion of women and elderly people. Among the risk factors, dyslipidemia and current smoking are more frequent among rehabilitated patients. These findings may help to modify the strategy for using cardiac rehabilitation after acute coronary syndrome, although it is an effective intervention for secondary prevention.

Dallongeville J, Cottel D, Arveiler D, Tauber JP, Bingham A, Wagner A, Fauvel J, Ferrières J, Ducimetière P, Amouyel P. · Service d'Epidémiologie et de Santé Publique, INSERM U 508, Institut Pasteur de Lille, Lille, France. · Ann Nutr Metab. · Pubmed #14646340 No free full text.

Abstract: AIMS: Metabolic disorders depend on genetic, hormonal and environmental factors, whose relations may differ between genders. Therefore, we compared the contribution of metabolic disorders to the metabolic syndrome in women and men. METHODS: To this end, we used a hierarchical classification statistical method to classify subjects into similarity groups according to clinical and biological parameters. Data were collected from 3,508 men and women aged 35-64 years, from a cardiovascular disease survey. RESULTS: In both women and men, hierarchical classification identified a cluster corresponding to the metabolic syndrome representing 14 and 15% of the women's and men's sample, respectively. In women, elevated body weight (women's Z-score: 1.59 vs. men's Z-score: 1.29; p < 0.005), waist girth (1.62 vs. 1.30; p < 0.001) and low HDL cholesterol (-0.95 vs. -0.75; p < 0.05) were significantly larger contributors to the metabolic syndrome than in men. In contrast, systolic (0.59 vs. 0.95; p < 0.0001) and diastolic (0.55 vs. 0.99; p < 0.0001) blood pressure and apolipoprotein B (0.51 vs. 0.71; p < 0.0001) contributed significantly less in women than in men. Finally, insulin (n.s.), glucose (n.s.), triglycerides (n.s.) and LDL-cholesterol (n.s.) contributions were not different between genders. CONCLUSION: These results are consistent with the concept that a clustering of metabolic disorders occurs frequently in both women and men. However, the contribution of several metabolic disorders to the metabolic syndrome is different in men and women. This finding supports the concept that different criteria are necessary to define the metabolic syndrome in women and men.

Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Perret B, Ferrières J. · INSERM U558, Faculté de Médecine Purpan, Toulouse, France. · Am J Cardiol. · Pubmed #14583365 No free full text.

Abstract: The effects of the apolipoprotein E epsilon and angiotensin-converting enzyme insertion/deletion alleles on lipid levels and hypolipidemic drug treatment was assessed in 400 men with stable angina pectoris or healed myocardial infarction and 338 healthy controls. The data indicate that epsilon4 carriers have increased total and low-density lipoprotein cholesterol levels, that the epsilon4 allele unfavorably decreases the efficiency of statin treatment, and that the angiotensin-converting enzyme insertion/deletion polymorphism exerts no significant effect, with the exception of an increase in apolipoprotein E levels.

Marques-Vidal P, Montaye M, Ruidavets JB, Amouyel P, Ferrières J. · INSERM U558, Faculty of Medicine Purpan, Toulouse, France. · Cardiovasc Drugs Ther. · Pubmed #12975599 No free full text.

Abstract: PURPOSE: To assess the trends of the cost of cardiovascular disease prevention in France for period 1986-1997. METHODS: MONICA population surveys conducted in two French Regions (Northern and Southwestern France). The individual costs of antihypertensive and hypolipidaemic drug treatment were established in 4765 subjects for the first (1985-1989) and the last (1995-1997) survey taking into account inflation rates and different daily posologies. RESULTS: After correcting for inflation, minimum and maximum daily cost of antihypertensive treatment remained stable or decreased in both genders. Minimum daily cost for hypolipidaemic drugs remained stable but maximum costs increased considerably in both genders. This was further aggravated by a doubling of the number of subjects under hypolipidaemic drug treatment between both surveys. CONCLUSIONS: Individual daily cost of antihypertensive treatment has decreased whereas cost of hypolipidaemic treatment has increased during period 1985-1997. The higher number of subjects on hypolipidaemic drug therapy further increased the national expenditure for this class of drugs.

Marques-Vidal P, Bongard V, Arveiler D, Amouyel P, Ducimetière P, Ferrières J. · INSERM U558, Faculté de médecine, département d'épidémiologie, 37, allées Jules Guesde, 31073 Toulouse. · Arch Mal Coeur Vaiss. · Pubmed #12055766 No free full text.

Abstract: AIM: To assess the cost of the preventive measures against hypertension and dyslipidemia in French subjects aged 35-64 years. METHODS: Cross-sectional study conducted in 433 men and 424 women from the three French centres participating in the WHO-MONICA Project and receiving antihypertensive and/or hypolipidemic drug therapy. RESULTS: In both genders, beta-blockers and ACE inhibitors were the most frequently prescribed antihypertensive drugs, and half of treated hypertensive subjects still had blood pressure levels beyond the normal limits, this percentage being lower in men and in Bas-Rhin. Daily cost of antihypertensive treatment ranged between 0.58 (minimum) and 1.72 [symbol: see text] (maximum) in men and between 0.54 and 1.46 [symbol: see text] in women, with no differences between centers. Fibrates were the most frequently prescribed hypolipidemic drug, and daily cost of treatment ranged between 0.33 and 1.33 [symbol: see text] in men and between 0.36 and 1.26 [symbol: see text] in women; in men, costs were lower in the Communauté Urbaine de Lille. Slightly more than half of the hyperlipidemic subjects had their LDL levels within normal values; no differences were found between centers or genders. Finally, the daily cost of "therapeutic inefficiency" for hypertension and dyslipidemia for age group 35-64 years in France was estimated to be over one million [symbol: see text]. CONCLUSION: The cost of the antihypertensive and hypolipidemic drug treatment is high and efforts should be undertaken in order to increase the efficiency of prevention.

Fauvel J, Bonnet E, Ruidavets JB, Ferrières J, Toffoletti A, Massip P, Chap H, Perret B. · Laboratoire de Biochimie III and INSERM U 326-IFR 30-Institut Claude de Préval, Toulouse University Hospital, Toulouse-Cédex, France. · AIDS. · Pubmed #11740190 No free full text.

Abstract: BACKGROUND: Long-term therapy with protease inhibitors (PI) is associated with hypertriglyceridaemia, low high-density lipoprotein (HDL) levels and accumulation of apolipoprotein (apo) E- and apo C-III-containing lipoproteins. OBJECTIVES: To evaluate the impact, on this dyslipaemic phenotype, of three polymorphisms of the apo C-III gene: two on an insulin response element and one in the 3'-region. Apo E genotypes were evaluated also. DESIGN: Sixty consecutive male patients attending the HIV follow-up consultation were included during a 3-month period. All patients received at least one PI. Apo C-III and apo E genotypes were determined. Besides routine bio-clinical examination, a detailed exploration of lipoproteins and of insulin secretion markers was carried out. METHODS: Plasma lipoparticles, insulin, proinsulin and C-peptide were measured by specific immuno-assays. Determination of apo C-III genotypes (-455C/T, -482C/T and SstI) and of apo E alleles (epsilon2, epsilon3 and epsilon4) were performed by amplification and endonuclease digestion and were confirmed by allele-specific oligonucleotide hybridization. RESULTS: Distribution of apo C-III alleles defined four major haplotypes. Carriers of the -455C variant had 30% lower levels of HDL-cholesterol than non-carriers. Plasma triglycerides increased according to the number of variant alleles. In multivariate analysis, a model including age, body mass index, clinical stage and treatment length, plasma insulin and apo C-III haplotypes explained around 43% of the HDL-cholesterol and triglycerides variability. Measurements of lipids before and after the use of PI demonstrated synergistic effects of the treatment and apo C-III variants on triglyceride levels. CONCLUSIONS: Apo C-III polymorphisms might identify a genetic predisposition to develop dyslipidaemia under PI therapy.

Lascaux-Lefebvre V, Ruidavets JB, Arveiler D, Amouyel P, Haas B, Cottel D, Bingham A, Ducimetière P, Ferrières J. · Department of Epidemiology, INSERM U558, Faculty of medicine, Toulouse, France. · Diabetes Metab. · Pubmed #11547225 links to  free full text

Abstract: OBJECTIVES: To assess the effect of parental histories of cardiovascular risk factors on risk factor clusters (RFC) in representative samples from three French populations (MONICA centers of Lille, Strasbourg, Toulouse). MATERIAL AND METHODS: In a representative cross-sectional study, we screened 1,291 males and 1,264 females, aged 35-64 years. Subjects were defined as RFC cases when they were affected by at least 2 disorders among, hypertension (systolic or diastolic blood pressure >=140/90 mmHg and/or antihypertensive drug), diabetes (physician-diagnosed diabetes and/or glycemia >=7.0 mmol/l and/or hypoglycemic drug), and dyslipidemia (triglycerides > 2.26 mmol/l and/or HDL-cholesterol<0.9 mmol/l in men and<1.2 mmol/l in women). Nineteen percent of the subjects were RFC cases. Parental histories of cardiovascular risk factors (hypertension, diabetes, hyperlipidemia) were positive if they were under 65. About 29% of the subjects had at least one parental history of risk factor. RESULTS: After adjustment for sex, age, educational level, sedentary lifestyle, alcohol consumption, body mass index, LDL cholesterol and center, parental histories of cardiovascular risk factors were significantly associated with the RFC. One, two, or at least three parental histories were significantly associated with increased odds of being RFC cases (adjusted OR 1.39 95% CI [1.05-1.82], 2.90 95% CI [1.91-4.40], 2.93 95% CI [1.41-6.08]). Furthermore, a maternal-only history vs a paternal-only history of hypertension or diabetes was associated with strong odds of being an RFC case. CONCLUSION: At least a single cardiovascular risk factor in parents was significantly associated with RFC in offspring, independently of environmental parameters.

Marques-Vidal P, Cambou JP, Ferrières J, Thomas D, Grenier O, Cantet C, Danchin N, Anonymous00004. · INSERM U518, Faculté de médecine Purpan, département d'épidémiologie, 37, allées Jules-Guesde, 31073 Toulouse. · Arch Mal Coeur Vaiss. · Pubmed #11494627 No free full text.

Abstract: The aim of this study was to evaluate the distribution and hospital treatment of cardiovascular risk factors in coronary patients. A transverse observational study was carried out in 77 cardiological centres throughout France. All patients with a history of myocardial infarction or of unstable angina during the month of January 1998 were enrolled. The clinical features of 1334 patients (71.4% men, 746 myocardial infarction, 588 unstable angina) on hospital admission were analysed. The prevalence of smoking, dyslipidaemia, hypertension and obesity was 49, 45, 42, 19 and 11% respectively in the men and 17, 46, 63, 23 and 10% respectively in the women. The number of treatable risk factors slightly decreased in the oldest age group. The prevalence of hypertension increased with age whereas smoking and dyslipidaemia decreased in both men and women. Obese and diabetic patients had more risk factors than the others. A little less than half of patients with dyslipidaemia were under no preventive measures (diet and/or lipid-lowering drugs) and 40% of men with a previous history of coronary artery disease continued to smoke. The authors conclude that men over 85 and women over 75 years of age have fewer risk factors than other age groups and the type of risk factor varies with age. The treatment of dyslipidaeamia and smoking is still inadequate and should be improved.